1. Home
  2. TXG vs JANX Comparison

TXG vs JANX Comparison

Compare TXG & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 10x Genomics Inc.

TXG

10x Genomics Inc.

HOLD

Current Price

$17.77

Market Cap

1.6B

Sector

Industrials

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$16.51

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TXG
JANX
Founded
2012
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
TXG
JANX
Price
$17.77
$16.51
Analyst Decision
Buy
Strong Buy
Analyst Count
13
12
Target Price
$14.73
$62.00
AVG Volume (30 Days)
3.3M
2.3M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$641,814,000.00
$10,000,000.00
Revenue This Year
$4.50
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.92
N/A
52 Week Low
$6.78
$15.51
52 Week High
$20.34
$71.71

Technical Indicators

Market Signals
Indicator
TXG
JANX
Relative Strength Index (RSI) 57.17 29.81
Support Level $17.06 $15.51
Resistance Level $19.29 $35.34
Average True Range (ATR) 1.08 1.91
MACD -0.10 -1.87
Stochastic Oscillator 48.84 4.34

Price Performance

Historical Comparison
TXG
JANX

About TXG 10x Genomics Inc.

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: